SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is actively discussed after its obesity drug's trial results did not match a key rival, leading to a significant stock dip; however, this is tempered by regulatory actions against unauthorized compounded GLP-1s and robust demand for its oral weight-loss treatment, causing a split in community sentiment between caution and buying the dip.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending following the FDA approval of Bysanti (milsaperidone) with New Chemical Entity status and patent protection until 2044, igniting community speculation about a significant short squeeze and potential buyout offers from larger pharmaceutical firms. Investors are weighing the drug's long-term revenue potential against ongoing concerns of market manipulation and potential dilution.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after reporting stellar Phase 2 S-OLARIS trial results for sonelokimab in axial spondyloarthritis, demonstrating high efficacy and potential disease-modifying effects. This positive data, coupled with a major institutional investor significantly increasing its stake and an anticipated Investor Day, has ignited strong community discussion about its "best-in-class" potential, a potential re-rating, and a short squeeze.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is in focus due to its strong Q4 earnings and bullish 2026 outlook, which contrasts with a competitor's subdued guidance, solidifying its leading position in the GLP-1 market. The community is actively discussing Lilly's sustained demand and pipeline strength, especially after its obesity drug demonstrated superior performance in a head-to-head trial against a rival and amid regulatory actions against compounded alternatives.

Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Redwood City MD.

Arcellx Inc

Recent positive clinical data for Arcellx's multiple myeloma CAR-T therapy, anito-cel, showcases strong efficacy and a differentiated safety profile, driving current conversation. An expanded strategic partnership and investment from Kite (Gilead), combined with the recent lifting of a partial clinical hold, reinforces market confidence and highlights the company's competitive edge in the cell therapy landscape.

Domino's Pizza, Inc. engages in the management of a network of company-owned and franchise-owned pizza stores. It operates through the following segments: U.S. Stores, International Franchise, and Supply Chain. The U.S. Stores segment consists primarily of franchise operations. The International Franchise segment comprises a network of franchised stores. The Supply Chain segment manages regional dough manufacturing and food supply chain centers. The company was founded by James Monaghan and Thomas Stephen Monaghan in 1960 and is headquartered in Ann Arbor, MI.

Dominos Pizza Inc

Dominos Pizza is drawing attention after its Q4 earnings report showcased solid results and strategic investments, further amplified by Berkshire Hathaway's increased stake. The community is actively debating if its focus on value and digital initiatives can continue to drive market share in a competitive restaurant environment.

Polygon

Polygon (POL) is generating significant community discussion due to its strategic pivot toward regulated payments and Real-World Assets, driven by new infrastructure like the AggLayer and surging on-chain usage, leading many to view it as a prime long-term accumulation opportunity despite current price action.

Direxion Shares ETF Trust - Direxion Daily Technology Bear -3X Shares

Direxion Daily Technology Bear 3X Shares

Direxion Daily Technology Bear 3X Shares (TECS) is trending as traders are aggressively taking bearish positions on the technology sector, driven by concerns over sliding AI stocks, sustained high interest rates, and perceived overvaluation of large-cap tech. The community is actively discussing an "AI boom downfall" and anticipating further market weakness, with many embracing inverse ETFs as a "safe money" play.

York Space Systems, Inc. engages in providing a comprehensive suite of mission-critical solutions for national security, government, and commercial customers. It offers a vertically integrated, full technology stack of solutions including design, production, integration, and operation of spacecraft with turnkey offerings to manage spacecraft and constellations throughout the entire mission lifecycle. The company was founded by Dirk Wallinger in January 2012 and is headquartered in Denver, CO.

York Space Systems Inc

York Space Systems (YSS), a recent IPO, is a major talking point as it has struggled to maintain its initial offering price, sparking community debate over its valuation and outlook. This comes amidst new analyst coverage and the filing of prospectuses for leveraged ETFs, highlighting its role in the evolving space and defense sector.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is trending as its Mainnet recently went live and a partnership with Aplix for a Japan-regulated stablecoin was announced, alongside its inclusion in Coinbase's institutional index for perpetual futures. This has sparked a polarized community discussion, with proponents highlighting these fundamental advancements for long-term potential, while critics remain skeptical given the token's continued price performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Liberty All-Star Growth Fund, Inc. January 2026 Monthly Update

Below is the January 2026 Monthly Update for the Liberty All-Star Growth Fund, Inc. (NYSE: ASG). Liberty All-Star Growth Fund, Inc. Ticker: ASG Monthly Update, January 2026 Investment Approach: Fund...

Liberty All-Star Growth Fund, Inc. Declares Distribution

The Board of Directors of Liberty All-Star Growth Fund, Inc. (NYSE: ASG) has declared a distribution of $0.12 per share payable on March 9, 2026 to shareholders of record on January 22, 2026. This...

Liberty All-Star Growth Fund, Inc. October 2025 Monthly Update

Below is the October 2025 Monthly Update for the Liberty All-Star Growth Fund, Inc. (NYSE: ASG). Liberty All-Star Growth Fund, Inc. Ticker: ASG Monthly Update, October 2025 Investment Approach: Fund...

Liberty All-Star Growth Fund, Inc. September 2025 Monthly Update

Below is the September 2025 Monthly Update for the Liberty All-Star Growth Fund, Inc. (NYSE: ASG). Liberty All-Star Growth Fund, Inc. Ticker: ASG Monthly Update, September 2025 Investment Approach...

Liberty All-Star Growth Fund, Inc. operates as a closed-end investment fund/investment trust. Its investment objective is to seek long-term capital appreciation through investment primarily in a diversified portfolio of equity securities. The company was founded on March 14, 1986 and is headquartered in Denver, CO.

Current Price	$5.19
Prev Close	$5.19
Open	$5.19
Dividend Yield	8.32%
50-Day Moving Average	$5.31
Beta	1.09
Avg. Volume	287,007.05
PE Ratio	9.08

52-Week High	$5.69
52-Week Low	$4.01
Market Capitalization	$321.57M
EPS (Annual)	$0.82
Price to Book	0.88
Revenue Per Employee	N/A

ASG
Liberty All Star Growth Fund Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest ASG News

ASGLiberty All Star Growth Fund Inc.